# Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-first-quarter-2026-financial-results-and-provides-corporate-update
Ticker: CMMB
Company: Chemomab Therapeutics
Source: Chemomab Therapeutics
Published: 2026-05-14 12:00 EST
Original Source URL: https://investors.chemomab.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-14 12:00 EST — [Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Chemomab Therapeutics
- 2026-03-19 12:00 EST — [Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-year-end-and-fourth-quarter-2025-financial-results-and-provides-a-corporate-update) — Source: Chemomab Therapeutics
- 2026-02-17 13:00 EST — [Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-to-participate-in-oppenheimer-36th-annual-healthcare-life-sciences-conference) — Source: Chemomab Therapeutics
- 2025-12-02 13:00 EST — [Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-nebokitug-phase-2-spring-trial-results-in-primary-sclerosing-cholangitis-published-in-the-american-journal-of-gastroenterology) — Source: Chemomab Therapeutics
- 2025-11-24 13:00 EST — [Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit](https://biopharmsignal.com/news/CMMB/chemomab-to-participate-in-oppenheimer-s-movers-in-rare-disease-summit) — Source: Chemomab Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)